Investor Relations
News
Board of Directors
Andrew Morris
Eric Brouwer
Donna Padavan
Adolfo Velazquez
Paul Gold
Medical Advisory Board
Samir Makani, MD
Chief Medical Advisor,
Head of Interventional Pulmonology
Coastal Pulmonary Assocs.
Scripps Health Network
Eldar Priel, MD
Principal Investigator, Medical Advisor, Associate Professor
Firestone Institute for Respiratory Health, McMaster University
Ashgar Naqvi, MD
Medical Advisor - Pathology, Associate Professor
Firestone Institute for Respiratory Health, McMaster University
Milestones
-
January 2026
Proprietary Engineered Antibodies Completed
-
December 2025
Clinical Study 1: Initial Results Confirm Sample Characterization Objectives
-
September 2025
Senior Technical Advisor Mike Hale added to Scientific Advisory Board
-
August 2025
Launched clinical sample collection study with Scripps Health; first 15 patients enrolled and specimens collected
-
July 2025
Medical University of South Carolina added as Clinical Partner
-
May 2025
Closed Funding Round with $2.3M Reg D Financing
-
December 2024
First Patients Enrolled in Clinical Study
-
November 2024
Launched First Clinical Study
-
October 2024
Second Patent Filed
-
September 2024
• EB-BIO Patent License Acquired
• 4000th verifi LUNG Test Cartridge Run in Lab -
July 2024
• Tungsten Collaborative Signed to Complete Industrial Design for ROSE Diagnostics
• Strategic Agreement Signed with AXXIN for verifi-1 Point-of-Care Reader -
June 2024
• Creative Destruction Lab Alumni
• $1M Seed Round Closed with Health Care Industry Angel-Lead Investors -
March 2024
• Provisional Patent Filed
• 1st Q-Sub Pre-Submission Meeting with FDA -
February 2024
Developed a 5 Minute Test Prototype
-
September 2023
• First In-Patient Prototype Tested
• Signed Key Opinion Leaders -
August 2023
Developed an 8 Minute Test Prototype
-
July 2023
Incorporation
-
March 2023
Developed a 10 Minute Test Prototype
Milestones
-
Proprietary engineered antibodies completed
-
Clinical Study 1: initial results confirm sample characterization objectives
-
Senior Technical Advisor Mike Hale joins the Scientific Advisory Board
-
Clinical sample collection begins with Scripps Health; 15 patients enrolled
-
Medical University of South Carolina added as a clinical partner
-
Closed $2.3M Reg D funding round
-
Initial patient enrollment in clinical study
-
First clinical study launched
-
Second patent filed
-
EB-BIO patent license acquired
-
4,000th test cartridge completed
-
Industrial design contract signed
-
Reader partnership agreement established
-
Closed $1M seed round
-
Became a Creative Destruction Lab alumnus
-
Provisional patent filed
-
FDA pre-submission meeting held
-
Developed a 5-minute test prototype
-
First in-patient prototype test
-
Key opinion leaders signed
-
Developed an 8-minute test prototype
-
Company incorporated
-
Developed a 10-minute test prototype